Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Single-arm, Multi-center and Phase II Clinical Trial of Camrelizumab Combined With AVD (Epirubicin, Vincristine and Dacarbazine) in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Sponsor: Henan Cancer Hospital
This PHASE2 trial investigates Classical Hodgkin Lymphoma and is currently ongoing. Henan Cancer Hospital leads this study, which shows 10 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jun 2023 — Jun 2024 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2019 — Jul 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Henan Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .